Hangzhou Diagens Biotechnology Co., Ltd. (Diagens) announced that, in line with Rule 2.07 of the Hong Kong Stock Exchange Listing Rules and the paperless listing regime effective since 31 December 2023, it will henceforth provide all corporate communications solely through electronic channels.

Effective immediately, English and Chinese versions of future documents—including directors’ reports, annual and interim reports, notices of meeting, listing documents, circulars and proxy forms—will be posted on both the company’s website (www.diagens.com) and HKEXnews (www.hkexnews.hk). Printed copies will no longer be mailed by default.

Non-registered shareholders who wish to receive these materials must:

1. Submit their email addresses to the banks, brokers, custodians or other intermediaries through which their shares are held; or 2. Request hard-copy documents by completing and returning the reply form to the H-share registrar, Computershare Hong Kong Investor Services Limited, or by emailing ir@diagens.com with their name, address and print request.

The board is chaired by Song Ning, who signed the shareholder notice dated 20 April 2026. For further queries, shareholders are directed to contact the company via the same investor-relations email address.